Natco Pharma’s high-stakes game of risk and reward. Will it pay off?
After a stellar FY24 performance, Natco Pharma’s stock has taken a hit. What’s next for the company as it faces crucial ...
A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
The shot was 100% effective in preventing HIV infections in a study of women, and results published Wednesday show it worked ...
No-Moat UCB Focuses on Expanding Disease Indications for Bimzelx as Generics Weigh on Portfolio
We think UCB is in good financial health, with solid earnings and cash flow generation. UCB has deleveraged over the years, and it ended 2023 with about EUR 2.2 billion in net debt on its balance ...
Zacks.com on MSN1 天
Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio
Dr. Reddy’s Laboratories RDY is a major player in the generic drugs markets. The company reports its financial performance ...
MM&M1 天
Trump’s tariff proposal may impact prices of medical devices, generic drugs
Trump’s plans to slap tariffs on imported goods from overseas could have a negative impact on the medical devices industry, ...
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Bought by Quantbot Technologies LP
Quantbot Technologies LP lifted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 274.8% ...
The Mining Journal2 天
Twice-yearly shot could help end AIDS
“If the possibility of using generics has opened, I have faith that Mexico can join,” said Pérez. Byanyima said other ...